ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Remembering Etanercept & the Advent of the Biologic Era

Robert S. Katz, MD  |  February 10, 2020

As a veteran rheumatologist, I remember the clinical trials of etanercept’s (Enbrel’s) efficacy. And when the drug was first approved in 1998, I participated in those clinical trials and realized the effectiveness was astonishing. It was easy to tell which patients were treated with etanercept vs. those who received placebo, even though both groups were…

Filed under:Biologics/DMARDsSpeak Out Rheum Tagged with:etanerceptSpeak Out Rheumatology

Are Your Patients at Risk? Advocacy Matters

Kimberly Retzlaff  |  February 6, 2020

When insurance company practices put patients at risk, advocacy is an important tool physicians can use to make a real difference. You can make a difference.

Filed under:InsuranceLegislation & Advocacy Tagged with:ACR Insurance Subcommittee (ISC)AdvocacyBrian LogginsChris MorrisDr. Chris PhillipsGovernment Affairs Committee (GAC)Norman B. Gaylis

According to MRI, Ultrasound Guidance Does Not Improve Treat-to-Target in RA

Reuters Staff  |  February 5, 2020

NEW YORK (Reuters Health)—Ultrasound guidance does not improve the effectiveness of treat-to-target therapy in rheumatoid arthritis (RA), new findings confirm. “Incorporating ultrasound information in treatment decisions did not lead to reduced MRI inflammation or less structural damage compared with a conventional treatment strategy,” Dr. Ulf Sundin of Diakonhjemmet Hospital, Oslo, and colleagues write in Rheumatology….

Filed under:ConditionsRheumatoid Arthritis Tagged with:imagingMagnetic resonance imaging (MRI)MRIRheumatoid Arthritis (RA)Treat-to-TargetUltrasound

Risankizumab Demonstrates Superiority to Secukinumab for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  February 5, 2020

In a phase 3, comparator study in adults with plaque psoriasis, patients taking
risankizumab achieved greater skin clearance than those taking secukinumab…

Filed under:Drug Updates Tagged with:plaque psoriasisrisankizumabsecukinumab

Even with Insurance, Fewer Americans Seeing Primary Care Providers

Lisa Rapaport  |  February 4, 2020

(Reuters Health)—Almost half of U.S. adults with private health insurance are not visiting primary care providers for routine care or sick visits, a new study suggests. Between 2008 and 2016, the number of annual primary care visits for every 100 people with private health insurance declined by 22%, from 169.5 to 134.3, the study found….

Filed under:Professional Topics

Varicella Zoster Virus Not Associated with Giant Cell Arteritis Pathogenesis

Carina Stanton  |  February 4, 2020

Researchers suggest antiviral therapy is not appropriate for patients with GCA, based on their study findings and related research…

Filed under:ConditionsVasculitis Tagged with:GCAgiant cell arteritis (GCA)varicella zoster virus

Update on the Management of Takayasu Arteritis

Lara C. Pullen, PhD  |  February 4, 2020

A rare form of large vessel vasculitis, Takayasu arteritis persents with no clear patterns, with patients experiencing vascular symptoms, as well as such systemic symptoms as fever and weight loss. A systematic literature review found evidence to guide rheumatologists in monitoring and treating their patients with Takayasu arteritis…

Filed under:ConditionsVasculitis Tagged with:large-vessel vasculitisTakayasu’s ArteritisVasculitis

Canada & E.U. Approve Upadacitinib for RA

Michele B. Kaufman, PharmD, BCGP  |  January 28, 2020

Upadacitinib will soon be available to treat patients with moderate to severe rheumatoid arthritis in Canada and the E.U…

Filed under:Biologics/DMARDsDrug Updates Tagged with:CanadaEuropean UnionRheumatoid Arthritis (RA)U.S. Food and Drug Administration (FDA)upadacitinib

Increased Risk of Inflammatory Arthritis with Hidradenitis Suppurativa

Will Boggs, MD  |  January 27, 2020

NEW YORK (Reuters Health)—Patients with hidradenitis suppurativa face an increased risk of developing inflammatory arthritis, according to findings from a claims database. “We observed increased risks of developing ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis (RA) among patients with hidradenitis suppurativa when compared with those without hidradenitis suppurativa,” says Maria C. Schneeweiss, MD, of Brigham…

Filed under:Axial SpondyloarthritisConditions Tagged with:Hidradenitis suppurativaInflammatory arthritisrisk

New Gabapentinoid Warning Labels

Michele B. Kaufman, PharmD, BCGP  |  January 23, 2020

Gabapentinoid products will now carry warning labels about the risks of respiratory distress when combined with opioids and other nervous system and respiratory depressants…

Filed under:Uncategorized Tagged with:Drug SafetyFDAgabapentinoidsU.S. Food and Drug Administration (FDA)

  • « Previous Page
  • 1
  • …
  • 112
  • 113
  • 114
  • 115
  • 116
  • …
  • 329
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences